联合检测CA125、IL-10和外周血淋巴细胞主要组织相容性复合体Ⅱ诊断非霍奇金淋巴瘤

Joint detection serum CA125, interleukin-10 and peripheral blood lymphocytes MHCⅡ level for diagnose non-Hodgkin lymphomas

目的探讨血清CA125、IL-10和外周血淋巴细胞主要组织相容性复合体(MHC)Ⅱ联合检测在非霍奇金淋巴瘤诊断中的价值。方法试验组92例非霍奇金淋巴瘤患者,对照组50名正常健康人。全自动电化学发光分析仪检测血清CA125,ELISA方法检测IL-10,流氏细胞仪检测淋巴细胞MHCⅡ分子荧光强度。结果非霍奇金淋巴瘤患者CA125为(82±35)U/ml,IL-10为(286±83)pg/ml,淋巴细胞MHCⅡ分子平均荧光强度为168±27,它们与对照组比较有显著性差异(P<0.01)。联合检测血清CA125、IL-10和外周血淋巴细胞MHCⅡ,非霍奇金淋巴瘤的敏感性提高为92%,阴性预测值均提高为97%。结论联合检测血清CA125、IL-10和外周血淋巴细胞MHCⅡ能更好地诊断非霍奇金淋巴瘤。

Objective To discuss diagnostic value of joint detection serum CA125, IL-10 and peripheral blood lymphocytes MHCⅡ level in patients with Non-Hodgkin＆#39;s lymphomas. Methods 92 patients with non-Hodgkin＆#39;s lymphomas in experimental group and 50 normal healthy people in control group. Serum CA125 were measured by fully automated electrochemiluminescence analyzer, interleukin-10 were detected by enzyme-linked immunosorbent assay （ELISA）, MHCⅡ molecule fluorescence intensity were detected by flow cytometry. Results Non-Hodgkin＆#39;s lymphomas patients serum CA125 were （82±35）U/ml, IL-10 were （286±83）pg/ml, peripheral blood lymphocytes MHCⅡ molecular median fluorescence intensity were 168±27, there were significant differences compared with control group（P＆lt;0.01）. Combination serum CA125, IL-10 and peripheral blood lymphocytes MHCⅡ（HLA-DR） level tests, sensitivity increased to 92%, and negative predictive value for diagnose non-Hodgkin＆#39;s lymphomas increased to 97%. Conclusion Together with joint detection of serum CA125, IL-10 and peripheral blood lymphocytes MHCⅡlevel tests, would provide a higher sensitivity level for diagnose Non-Hodgkin＆#39;s lymphomas.